25 May, 2017
The business is scheduled to report its next quarterly earnings results on Wednesday, August 2nd. The Wall Street forecast had projected $-0.26 per share, and the company reported EPS of $-0.28 - also a -6.67% negative surprise. For the next financial year, analysts expect that the company will post earnings of ($0.97) per share, with EPS estimates ranging from ($1.92) to ($0.28). Zacks Investment Research's earnings per share averages are a mean average based on a survey of analysts that follow Nektar Therapeutics.
Nektar Therapeutics (NKTR) failed to surprise the stock market in its last reported earnings when it earned -$0.42 a piece versus the consensus-estimated -$0.42.
Analysts expect AIA Group Ltd. (OTCMKTS:AAGIY) to report $0.00 EPS on May, 26. Nektar Therapeutics had a negative net margin of 98.87% and a negative return on equity of 8,769.15%. Revenue during the period amounted to $37.45M, while analysts were anticipating $40.67M. During the same period previous year, the business posted ($0.40) EPS.
Several analysts have recently issued reports on the stock. Its share price has risen 59.85% in three months and is up 11.64% for the last five trades. JPMorgan Chase & Co. set a $24.00 price target on Nektar Therapeutics and gave the company a "buy" rating in a report on Tuesday, March 21st.
A number of research analysts have recently issued reports on the company. BTIG Research upped their target price on shares of Nektar Therapeutics from $22.00 to $27.00 and gave the stock a "positive" rating in a research note on Tuesday, March 21st. Wall Street is only getting more bullish on the stock, with 9 of analysts who cover NKTR having a buy-equivalent rating. Currently, the stock has a 1 Year Price Target of $24.88. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Roth Capital set a $23.00 target price on shares of Nektar Therapeutics and gave the stock a "buy" rating in a research note on Saturday, March 4th. If you are reading this piece on another site, it was stolen and republished in violation of United States & global trademark & copyright legislation. Also, Director Christopher A. Kuebler sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, April 5th. The stock was sold at an average price of $21.70, for a total value of $3,906,000.00.
The counter witnessed a trading volume of 0.85 million shares versus an average volume of 0.16 million shares during last trading session. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
In other Nektar Therapeutics news, SVP Stephen K. Doberstein sold 1,701 shares of Nektar Therapeutics stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $12.39, for a total transaction of $929,250.00. The company's shares traded on stronger-than-usual volume today: $2.88M shares changed hands while the stock's average volume is 2.19M shares per day. The disclosure for this sale can be found here. Flinton Capital Management LLC boosted its position in Nektar Therapeutics by 11.1% in the first quarter. California State Teachers Retirement System now owns 274,242 shares of the biopharmaceutical company's stock worth $4,711,000 after buying an additional 2,300 shares during the last quarter. Municipal Employees Retirement System of MI increased its stake in shares of Nektar Therapeutics by 1.6% in the third quarter. Municipal Employees Retirement System of MI now owns 30,250 shares of the biopharmaceutical company's stock valued at $520,000 after buying an additional 490 shares in the last quarter. United Services Automobile Association increased its stake in Nektar Therapeutics by 4.4% in the third quarter. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued.
The stock has Return on Assets (ROA) of -39.9 percent. Finally, BlackRock Fund Advisors raised its position in Nektar Therapeutics by 7.3% in the third quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company's stock valued at $184,000 after buying an additional 784 shares in the last quarter. Insiders own 6.10% of the company's stock.
Nektar Therapeutics (NASDAQ:NKTR) traded down 0.14% during mid-day trading on Monday, reaching $21.07. The company maintains price to book ratio of 1.01 vs.an industry average at 1.57. The company rocked its 52-Week High of $24.88 and touched its 52-Week Low of $11.41. The stock's market capitalization is $2.98 billion.
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need.
